EcoDrugPlus

40s Ribosomal Protein S13

Ensembl ID : ENSDCDG00000009136
Gene Symbol: LOC114765799
3 Cross references
381 Possible Orthologues:

40s Ribosomal Protein S25

Ensembl ID : ENSDCDG00000000445
Gene Symbol: LOC114791825
3 Cross references
413 Possible Orthologues:

40s Ribosomal Protein S26-Like

Ensembl ID : ENSDCDG00000021159
Gene Symbol: LOC114769334
3 Cross references
322 Possible Orthologues:

40s Ribosomal Protein S28-Like

Ensembl ID : ENSDCDG00000004457
Gene Symbol: LOC114789050
3 Cross references
266 Possible Orthologues:

40s Ribosomal Protein S5

Ensembl ID : ENSDCDG00000019381
Gene Symbol: LOC114770277
3 Cross references
252 Possible Orthologues:

40s Ribosomal Protein S5-Like

Ensembl ID : ENSDCDG00000022741
Gene Symbol: LOC114789730
2 Cross references
201 Possible Orthologues:

40s Ribosomal Protein Sa

Ensembl ID : ENSDCDG00000002337
Gene Symbol: LOC114787164
3 Cross references
518 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSDCDG00000004985
Gene Symbol: NT5E
3 Cross references
206 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a-Beta-Like

Ensembl ID : ENSDCDG00000022724
Gene Symbol: LOC114786431
3 Cross references
137 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSDCDG00000004982
Gene Symbol: HTR1B
3 Cross references
181 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSDCDG00000016254
Gene Symbol: HTR1E
3 Cross references
150 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSDCDG00000026790
Gene Symbol: HTR1F
3 Cross references
112 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).